Vimentin Variant 3 Detection for Malignant Tumor Assessment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for reliable molecular markers that can indicate the presence or absence of malignant tumors and assess their malignancy, particularly for distinguishing between benign and malignant neoplasia and detecting metastatic potential.
Innovation Solution
The method involves determining the level of Vimentin variant 3 (Vim3) in an individual's blood serum and/or the accumulation of Vim3 polypeptide in cell nuclei, which indicates the presence of a malignant tumor, especially with a high propensity to metastasize.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional tumor detection methods are used, then detection capability is limited, but reliability of malignancy assessment is insufficient
Solution Approach 1:
The patent changes the detection parameter from traditional tumor markers to Vimentin variant 3 (Vim3) protein levels and nuclear accumulation patterns. This parameter change enables more reliable malignancy assessment by detecting specific molecular signatures that differentiate malignant from benign tumors, while maintaining ease of detection through standard immunohistochemistry and Western blot techniques
Solution Approach 2:
The patent replaces traditional mechanical/pathological examination methods with molecular biology-based detection methods. By using immunohistochemistry, Western blot, and other molecular techniques to detect Vim3 protein expression and nuclear accumulation, the method achieves higher reliability in malignancy assessment while maintaining practical detectability
2Measurement precision
If early detection methods are implemented, then curability is improved, but ability to detect malignant tumors specifically is insufficient
Solution Approach 1:
The patent applies local quality by detecting Vim3 expression specifically in nuclear compartments and measuring its unique C-terminal sequence. This localized detection approach provides high measurement precision for malignant tumor identification, as nuclear Vim3 accumulation is a specific feature of malignant cells, while enabling early detection through sensitive molecular assays that can detect low-level expression before clinical symptoms appear
3Measurement precision
If Vim3 detection method is used, then detection accuracy for malignant tumors is improved, but complexity of the detection method increases
Solution Approach 1:
The patent extracts and detects only the specific C-terminal sequence of Vimentin variant 3 (amino acids 391-413: NLRGKHFISL) using targeted antibodies and PCR primers. This extraction approach maintains high detection accuracy by focusing on the unique malignant-specific region of Vim3, while simplifying the overall detection method by eliminating the need to detect entire protein structures or use multiple non-specific markers
Data Source
AI summary
The present invention relates to methods for detecting a malignant tumor in an individual by means of determining the Vimentin variant 3 (Vim3) level in the individual's blood serum S and/or the accumulation of Vim3 polypeptide in cell nuclei. Furthermore, the present invention refers to an antineoplastic agent for use in a method for treating an individual bearing a malignant tumor, wherein said antineoplastic agent is a Vim3 inhibitor and/or wherein the malignant tumor is endothelin B receptor negative.